Condition: Myotonic Dystrophy 1 · Sponsor: PepGen Inc
The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.
This description comes directly from the study's public registry record.
PepGen · 781-797-0979 · clinicaltrials@pepgen.com
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Recruiting |
| Ottawa Hospital Research Institute (OHRI) | Ottawa, Ontario, Canada | Recruiting |
| CIUSSS du Saguenay-Lac-Saint-Jean | Chicoutimi, Quebec, Canada | Recruiting |
| Montreal Neurological Institute | Montreal, Quebec, Canada | Recruiting |
| Pacific Clinical Research Network Auckland | Takapuna, Auckland, New Zealand | Active Not Recruiting |
| Salford Royal Hospital | Salford, England, United Kingdom | Recruiting |
| University College London Hospitals NHS Foundation Trust | London, UK, United Kingdom | Recruiting |
| Newcastle Upon Tyne Hospitals | Newcastle upon Tyne, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06667453